Compare GABC & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GABC | MPLT |
|---|---|---|
| Founded | 1910 | 2018 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 1995 | N/A |
| Metric | GABC | MPLT |
|---|---|---|
| Price | $51.06 | $13.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $47.67 | $32.67 |
| AVG Volume (30 Days) | 152.3K | ★ 1.4M |
| Earning Date | 04-27-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | ★ 8.13 | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $487,401,000.00 | N/A |
| Revenue This Year | $16.78 | N/A |
| Revenue Next Year | $3.98 | N/A |
| P/E Ratio | $58.00 | ★ N/A |
| Revenue Growth | ★ 37.80 | N/A |
| 52 Week Low | $37.19 | $9.10 |
| 52 Week High | $52.23 | $40.43 |
| Indicator | GABC | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
German American Bancorp Inc is a bank holding company. The lines of business include the core banking segment and the wealth management segment. The core banking segment involves attracting deposits from the general public and using those funds to originate consumer, commercial, and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services, which involve providing trust, investment advisory, brokerage, and retirement planning services to customers. The company generates the majority of its revenue from the core banking segment.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.